|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Collaboration and other research and development revenues | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Restructuring charges | |||||
| Restructuring and impairment charges | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other income (expense), net: | |||||
| Interest expense related to sale of future revenues | |||||
| Interest income, net | |||||
| Other expense, net | |||||
| Total other income (expense), net | |||||
| Net loss | |||||
| Net loss per share, basic (in dollars per share) | |||||
| Net loss per share, diluted (in dollars per share) | |||||
| Weighted-average common shares outstanding, basic (in shares) | |||||
| Weighted-average common shares outstanding, diluted (in shares) |
Loading...
